AstraZeneca-Bristol Myers Talks Stir Market Volatility, Face Steep Regulatory Hurdles
Preliminary reports that AstraZeneca held early-stage talks with Bristol Myers Squibb about a potential combination that would create a nearly $400 billion pharmaceutical company prompted a sharp market response. AstraZeneca shares dropped roughly 9% while Bristol Myers briefly rose about 6% in premarket trading before settling near unchanged. Supp…